Fludarabine (Fludara®) – B-cell Chronic Lymphocytic Leukaemia – 2nd line treatment – as per NICE TA 29

Drug Name (Brand)	Fludarabine *(Fludara®)*
Indication	B-cell Chronic Lymphocytic Leukaemia – 2nd line treatment – as per NICE TA 29
Traffic Light Classification	Red
NICE TA (plus link)	Overview \| Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia \| Guidance \| NICE
Further Information: NICE recommendations, summary of meeting discussions, links to additional supporting docs etc. NICE September 2001: Oral fludarabine is recommended as second line therapy for B-cell chronic lymphocytic leukaemia (CLL) for patients who have either failed, or are intolerant of, first line chemotherapy, and who would otherwise have received combination chemotherapy of either: a) cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP); b) cyclophosphamide, doxorubicin and prednisolone (CAP) or c) cyclophosphamide, vincristine and prednisolone (CVP). March 2008: The TAG recommended that all oral anticancer medicines identified by the National Patient Safety Agency (NPSA) in the Rapid Response Report “Risks of incorrect dosing of oral anti-cancer medicines” (January 2008), for which there are no locally agreed shared care protocols, are classified as Red (Hospital Only). NHS England Specialised Commissioning responsibility from April 2013.
Date of TAG recommendation / ratification		7/1/2003	Review Date